News Related to Peripheral T-Cell Lymphoma

Related coverage linked through entity extraction aliases.

Azacitidine and Chidamide Added to CHOP Improves OS but Not ORR in PTCL

Jul 24, 2026

A phase 3 trial of azacitidine and chidamide plus CHOP in untreated PTCL showed a significant overall survival improvement but no significant gains in response rate or progression-free survival. The study suggests molecular profiling could guide future therapies.

Global Oncology Market Projected to Reach $748 Billion by 2035 Amid Immunotherapy Growth

Feb 19, 2026

The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.